501 related articles for article (PubMed ID: 15042374)
21. Urokinase-induced mitogenesis is mediated by casein kinase 2 and nucleolin.
Dumler I; Stepanova V; Jerke U; Mayboroda OA; Vogel F; Bouvet P; Tkachuk V; Haller H; Gulba DC
Curr Biol; 1999 Dec 16-30; 9(24):1468-76. PubMed ID: 10607589
[TBL] [Abstract][Full Text] [Related]
22. Human urokinase-type plasminogen activator primes neutrophils for superoxide anion release. Possible roles of complement receptor type 3 and calcium.
Cao D; Mizukami IF; Garni-Wagner BA; Kindzelskii AL; Todd RF; Boxer LA; Petty HR
J Immunol; 1995 Feb; 154(4):1817-29. PubMed ID: 7836767
[TBL] [Abstract][Full Text] [Related]
23. Biotin-Chasing Assay to Evaluate uPAR Stability and Cleavage on the Surface of Cells.
Leksa V; Schiller HB; Stockinger H
Methods Mol Biol; 2018; 1731():39-47. PubMed ID: 29318541
[TBL] [Abstract][Full Text] [Related]
24. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors.
Gutova M; Najbauer J; Frank RT; Kendall SE; Gevorgyan A; Metz MZ; Guevorkian M; Edmiston M; Zhao D; Glackin CA; Kim SU; Aboody KS
Stem Cells; 2008 Jun; 26(6):1406-13. PubMed ID: 18403751
[TBL] [Abstract][Full Text] [Related]
25. Characterization of cell-associated plasminogen activation catalyzed by urokinase-type plasminogen activator, but independent of urokinase receptor (uPAR, CD87).
Longstaff C; Merton RE; Fabregas P; Felez J
Blood; 1999 Jun; 93(11):3839-46. PubMed ID: 10339491
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of the tumor-associated urokinase-type plasminogen activation system: effects of high-level synthesis of soluble urokinase receptor in ovarian and breast cancer cells in vitro and in vivo.
Magdolen V; Krüger A; Sato S; Nagel J; Sperl S; Reuning U; Rettenberger P; Magdolen U; Schmitt M
Recent Results Cancer Res; 2003; 162():43-63. PubMed ID: 12790320
[TBL] [Abstract][Full Text] [Related]
27. Detection of the receptor for the human urokinase-type plasminogen activator using fluoresceinated uPA.
Ciccocioppo R; Capri MG; Alberti S
J Histochem Cytochem; 1997 Sep; 45(9):1307-13. PubMed ID: 9283618
[TBL] [Abstract][Full Text] [Related]
28. Distinct patterns of urokinase receptor (uPAR) expression by leukemic cells and peripheral blood cells.
Jardí M; Inglés-Esteve J; Burgal M; Azqueta C; Velasco F; López-Pedrera C; Miles LA; Félez J
Thromb Haemost; 1996 Dec; 76(6):1009-19. PubMed ID: 8972026
[TBL] [Abstract][Full Text] [Related]
29. Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.
Ploug M; Ellis V; Danø K
Biochemistry; 1994 Aug; 33(30):8991-7. PubMed ID: 8043585
[TBL] [Abstract][Full Text] [Related]
30. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
31. Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.
Yebra M; Goretzki L; Pfeifer M; Mueller BM
Exp Cell Res; 1999 Jul; 250(1):231-40. PubMed ID: 10388537
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells.
Hjertner O; Qvigstad G; Hjorth-Hansen H; Seidel C; Woodliff J; Epstein J; Waage A; Sundan A; Börset M
Br J Haematol; 2000 Jun; 109(4):815-22. PubMed ID: 10929035
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
34. Structure-function relationships in the interaction between the urokinase-type plasminogen activator and its receptor.
Ploug M
Curr Pharm Des; 2003; 9(19):1499-528. PubMed ID: 12871065
[TBL] [Abstract][Full Text] [Related]
35. Urokinase plasminogen activator induces human smooth muscle cell migration and proliferation via distinct receptor-dependent and proteolysis-dependent mechanisms.
Stepanova V; Mukhina S; Köhler E; Resink TJ; Erne P; Tkachuk VA
Mol Cell Biochem; 1999 May; 195(1-2):199-206. PubMed ID: 10395084
[TBL] [Abstract][Full Text] [Related]
36. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors.
Montuori N; Cosimato V; Rinaldi L; Rea VE; Alfano D; Ragno P
Thromb Haemost; 2013 Feb; 109(2):309-18. PubMed ID: 23238745
[TBL] [Abstract][Full Text] [Related]
37. EGF-stimulated migration in ovarian cancer cells is associated with decreased internalization, increased surface expression, and increased shedding of the urokinase plasminogen activator receptor.
Henic E; Sixt M; Hansson S; Høyer-Hansen G; Casslén B
Gynecol Oncol; 2006 Apr; 101(1):28-39. PubMed ID: 16263158
[TBL] [Abstract][Full Text] [Related]
38. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
Pluskota E; Soloviev DA; Plow EF
Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
[TBL] [Abstract][Full Text] [Related]
39. Urokinase anchors uPAR to the actin cytoskeleton.
Bernstein AM; Greenberg RS; Taliana L; Masur SK
Invest Ophthalmol Vis Sci; 2004 Sep; 45(9):2967-77. PubMed ID: 15326109
[TBL] [Abstract][Full Text] [Related]
40. A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Ploug M; Eriksen J; Plesner T; Hansen NE; Danø K
Eur J Biochem; 1992 Sep; 208(2):397-404. PubMed ID: 1325906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]